Hutchmed (China) Limited (HCM) has released an update.
HUTCHMED has announced the advancement of its Phase II/III clinical trial for sovleplenib, an investigational drug aimed at treating warm antibody autoimmune hemolytic anemia (wAIHA) in China. Positive results from the trial could lead to a New Drug Application, addressing a condition with few existing treatments. The trial will assess sovleplenib’s safety and efficacy, with the primary goal being a durable response in patients’ hemoglobin levels.
For further insights into HCM stock, check out TipRanks’ Stock Analysis page.
